David MOULIN

My research activity lies at the interface between pathophysiology and pharmacology in the field of chronic inflammation, particularly joint inflammation. After completing my PhD in 2005 on the anti-arthritic properties of PPAR agonists, I conducted my postdoctoral fellowship in Geneva, where I worked on cytokines of the IL-1 family. During this period, one of my major contributions was the characterization of the role of IL-33 in mast cells (a study that has been cited 272 times to date).

Since my recruitment in 2008 as a CNRS Research Scientist, I have led several projects simultaneously, achieving thematic independence and financial autonomy. These projects converge around a single overarching concept: immunometabolism, which is altered in chronic inflammatory diseases.

In recent years, I have moved closer to clinical research in order to test our fundamental hypotheses against the realities of chronic inflammatory diseases, which are becoming increasingly prevalent in our societies. This shift has been accompanied by a significant evolution in my research focus, including an increased engagement with gut microbiota studies, in connection with my fundamental research on the role of nuclear receptors and adipokines in the regulation of inflammation.

I am actively involved/leading national and international research programs such as ANR, PHRC, CPRC, the Pfizer Passerelle program, and Eurostars project. In addition, he serves on the board of directors of the French Society for Mineralized Tissue Biology, participates in the strategic council of the Arthritis Foundation, and chairs the “Immunity and Inflammation” working group within the INSERM ROADTO2030 network.
Co-leader of team CImIND.

• Jessica BETTINGER
• Jordan BROUARD